Deep Longevity: Insilico spinout clocks biological age

Deep Longevity’s biomarkers could be used to measure the efficacy of anti-aging therapeutics

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical trials and in clinical practice.

Alex Zhavoronkov, founder and CEO of Deep Longevity Inc., said the

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers